Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: A single-institution series

Blood

Volumn 123, Issue 2, 2014, Pages 177-183

  Rosenberg, Joshua D ^a   Burian, Carol ^a   Waalen, Jill ^b   Saven, Alan ^a  

^a SCRIPPS CLINIC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; RITUXIMAB;

ADULT; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; SECOND CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RECURRENCE; REMISSION INDUCTION; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892637595     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-508754     Document Type: Article

References (20)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-630.
2. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
3. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984;310(1):15-18. (Pubitemid 14212475)
4. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13(4):974-982.
5. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol. 1989;7(2):168-172. (Pubitemid 19048448)
6. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5):891-896. (Pubitemid 46606450)
7. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003; 102(3):810-813. (Pubitemid 36917768)
8. Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymph. 2011; 52(Suppl 2):75-78.
9. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairycell leukemia. N Engl J Med. 2012;366(21): 2038-2040.
10. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16):1117-1121. (Pubitemid 20149529)
11. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92(6): 1918-1926. (Pubitemid 28446680)
12. Kochanek KD, Xu JQ, Murphy SL, et al. Deaths: final data for 2009. Natl Vital Stat Rep. 2011; 60(3):1-117.
13. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (vintage 2009 populations). Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed November 12, 2013.
14. Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood. 1996;88(6):1954-1959. (Pubitemid 26307896)
15. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol. 1997;15(3):1138-1142. (Pubitemid 27106300)
16. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-an unmarried person of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18(9):1476-1481. (Pubitemid 39264069)
17. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106(1):241-246. (Pubitemid 40967199)
18. Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010;115(10): 1893-1896.
19. Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood. 1996;87(4):1556-1560. (Pubitemid 26056921)
20. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2- chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res. 1999;5(7):1665-1670. (Pubitemid 29334443)